

## **Cosponsor H.R.1776 the End Tuberculosis Now Act of 2023**

### **Become a Cosponsor of H.R.1776 the Bipartisan End Tuberculosis Now Act of 2023**

**118<sup>th</sup> Cosponsors:** Bera, *Salazar*, Sherman, *Fitzpatrick*, Ross, Crockett, Cohen, Trone, Espallat

**Endorsing Organizations:** American Lung Association, American Thoracic Society, America's TB Coalition, AVAC, Borgen Project, Christian Connections for International Health, Elizabeth Glaser Pediatric AIDS Foundation, Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, Georgia AIDS Coalition, Global Health Council, Global Health Technologies Coalition (GHTC), Infectious Disease Society of America, JSI, National TB Controllers Association, ONE Campaign, Partners in Health, R2H Action, RESULTS, Stop TB USA, TB Alliance, Treatment Action Group, Tuberculosis Roundtable, We Are TB

Dear Colleague:

Please join us in becoming a cosponsor of the End Tuberculosis Now Act of 2023.

Tuberculosis (TB) kills more people globally than HIV and malaria combined, and has alternated with COVID-19 as the leading infectious disease killer over the past 3 years. In October 2022, the World Health Organization reported the first increase of tuberculosis sickness and death in decades with almost 11 million sickened and 1.6 million killed by the disease around the world in 2021. Drug resistant TB is the leading cause of death from antimicrobial resistance (AMR) globally, including multidrug resistant (MDR) and extensively drug resistant (XDR) TB which are significantly more expensive to treat with higher rates of treatment failure. The Russian invasion of Ukraine is of particular concern, given that Ukraine has one of the highest burdens of MDR-TB in the world and is currently experiencing shortages of health supplies and care during the humanitarian crisis.

The End Tuberculosis Now Act of 2023:

- requires the U.S. to establish bold goals for reaching the most vulnerable populations to detect, cure and prevent all forms of TB globally;
- strengthens U.S. bilateral coordination with global organizations, including the Global Fund to Fight AIDS, TB, and Malaria, to develop and implement a comprehensive global TB response;
- catalyzes support for research and development (R&D) of new tools to prevent, diagnose, treat, and control TB, including drug-resistant strains of TB worldwide;
- improves the capacity of countries and affected communities with high burdens of TB to implement programs to prevent and control the spread of TB;

- requires annual reporting to Congress on U.S. TB activities and their impact, including progress in recovering from the negative effects of COVID-19 on TB; and
- evaluates the performance and the focus on impact of TB programs that are supported by U.S. bilateral assistance funding.

Many believe TB is a disease of the past, but it is still a real public health threat due to a lack of resources to properly identify, treat and prevent all forms of the disease and develop new, more effective tools to fight TB. *TB anywhere is TB everywhere* and this coordinated and comprehensive approach for supporting global TB challenges is needed to address the TB pandemic.

If you have questions or would like to sign on, please contact Emma Bruce at [Emma.Bruce@mail.house.gov](mailto:Emma.Bruce@mail.house.gov) (Bera) or John-Mark Kolb at [JohnMark.Kolb@mail.house.gov](mailto:JohnMark.Kolb@mail.house.gov) (Salazar).

Sincerely,

Ami Bera, M.D.  
Member of Congress

Maria Elvira Salazar  
Member of Congress